tbuckley/cabot-search huggingface dataset:
1706P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country phase I/IIa expansion cohort
Authors: J. Krystal, A.R. Khaki, A.I. Spira, A.R. Abdul Razak, D. Maslyar, D.M. Glatt, C.C. Hwang, A.N. Diep, M. Schmidt, R. Vold
Journal: Annals of Oncology (2024)
1727MO Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a &gt;350 sample study including a validation cohort
Authors: E.A. Connolly, D. Bucio-Noble, S. Cai, A. Singh, J. Koh, R. Karim, A. Lazar, R. Lim, R. Morey, G. Ratnayake, P. Hains, L. Ye, D. Ingram, C.L. Scott, P.J. Robinson, H. Barker, E.F. Nassif Haddad, L.G. Horvath, P. Grimison, R. Reddel
Journal: Annals of Oncology (2024)
1710P Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Authors: B. Blanchet, A.A. Puszkiel, A. Jouinot, M. Bennamoun, D. Maillet, D. Borchiellini, B. Laguerre, D. Pannier, M. Gross Goupil, C.M. Chevreau, P. Barthelemy, C. Tournigand, E. Coquan, G. Gravis, S. Kotti, W-H. Fridman, C. Sautes-Fridman, S. Oudard, C-M. Sun, Y-A. Vano
Journal: Annals of Oncology (2024)
1731P Phase II study of the CDK2/4/6 inhibitor TQB3616 capsules in patients with dedifferentiated liposarcomas (DDLPS)
Authors: J. Chen, Y. Zhou, X. Zhang, B. Li, None W. luo, Y. Deng, S. Wei, D. Wu, J. Liu, W. Guo, W. Xie, G. Qu, X. Wang, X. Wan
Journal: Annals of Oncology (2024)
1733P Update on gallant: A phase II study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab in previously treated sarcoma
Authors: N.S. Chawla, R. Cechini, V. Kumar, A.D. Agarwal, S. Jeffrey, N. Omelchenko, J. Ballon, G. Haroun, V.S. Chua Alcala, A. Moradkhani, S.P. Chawla, E.M. Gordon
Journal: Annals of Oncology (2024)
1728P Results of TNT: A phase II study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311]
Authors: S.P. Chawla, V. Kumar, N. Omelchenko, S. Jeffrey, A.D. Agarwal, R. Cechini, V.S. Chua Alcala, D. Quon, S. Wong, E.M. Gordon
Journal: Annals of Oncology (2024)
1692P A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Authors: X. Sheng, H. Luo, C. Kong, F. Liu, S. Wei, Z. Wang, Y. Guo, Y. Yin, H. Zhao, G. Li, B. Wu, Y. Li, K. Nan, M. Ke, T. Wu, J. Zhang, Z. Wang, X. Li, K. Lei, J. Guo
Journal: Annals of Oncology (2024)
1623P Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Authors: A. Crippa, A. Mortezavi, A. Discacciati, C.T. Karlsson, M.H. Strijbos, E. Jänes, G. Enblad, B. Sautois, A. Ullén, F. Stenner-Liewen, M.E. Hjälm-Eriksson, D.J. De Maeseneer, P. Schatteman, C. Ghysel, J. Oldenburg, J. Lindberg, P. Ost, M. Eklund, H. Grönberg, B. De Laere
Journal: Annals of Oncology (2024)
1723MO Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: Single-arm phase II study (AXAGIST)
Authors: P. Rutkowski, A. Klimczak, P. Teterycz, T. Switaj, P. Rogala, M.A. Pantaleo, K. Kozak
Journal: Annals of Oncology (2024)
1644P PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Authors: L. Broer, J. Oldenburg, A. Mortezavi, J. Lindberg, A. Discacciati, C.T. Karlsson, A. Ullén, E. Jänes, G. Enblad, L. Pettersson, M.N. Vigmostad, M.E. Hjälm-Eriksson, M. Olsson, P. Schatteman, C. Ghysel, B. De Laere, H. Grönberg, P. Ost, M. Eklund, A. Crippa
Journal: Annals of Oncology (2024)
1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Authors: N. Agarwal, A.A. Azad, J.C. Galceran, A.P. Fay, N. Matsubara, C. Szczylik, U. De Giorgi, J.Y. Joung, P.C. Fong, E. Voog, R.J. Jones, N.D. Shore, C. Dunshee, S. Zschäbitz, J. Oldenburg, X. Lin, D. Laird, M. Kalac, D. Kennedy, K. Fizazi
Journal: Annals of Oncology (2024)
1672P Living the waiting: Feelings and experiences data from cancer patients in the waiting room
Authors: C. Mosillo, G. Pontoni, A. Guida, G. Sirgiovanni, J. Foglietta, C. Zannori, M. Nunzi, J. Bonanni, M. Tagliaventi, S. Sabatini, D. Parriani, E. Garofoli, C. Proietti, S. Bracarda
Journal: Annals of Oncology (2024)
1721MO Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma
Authors: R.L. Jones, R. Groisberg, J-Y. Blay, H. Colman, M. de la Fuente, M. Milhem, P. Roxburgh, M.M. Chao, H. Tian, F. Duffaud, C.P. Massard, B.A. Van Tine
Journal: Annals of Oncology (2024)
1650P Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Authors: T. Dai, W. Han, S. Jiang, K. Li, H. Wang, D. Zhang, K. Tang, Y. He, X. Wang, J. Huang, C. He, X. Zhou, D. Zhang, C. Yang
Journal: Annals of Oncology (2024)
1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
Authors: E. Rosenbaum, L-X. Qin, M. Dickson, S. Movva, C.M. Kelly, J. Chan, P. Chi, L. Banks, M.L. Keohan, M. Gounder, R.G. Maki, J. Cho, M. Biniakewitz, R. Desir-Camille, J.P. Erinjeri, R. Lefkowitz, C. Antonescu, S. Singer, W.D. Tap, S.P. D'Angelo
Journal: Annals of Oncology (2024)
1696P A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Authors: S. George, U.N. Vaishampayan, A. Hutson, A. Groman, C.L. Roche, L. Herbst, R. Kallicharsn-Smith, A-M. DiRaddo, E. Farrell, D. Kilari, D. Gopalakrishnan, E. Heath, E. Wulff-Burchfield, L.J. Appleman, R. Parikh
Journal: Annals of Oncology (2024)
1729P Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma
Authors: A.D. Agarwal, S. Jeffrey, R. Cechini, V. Kumar, N. Omelchenko, None J. ballon, A. Moradkhani, V.S. Chua Alcala, N.S. Chawla, S. Mahesh, S.P. Chawla, E.M. Gordon
Journal: Annals of Oncology (2024)
1722MO Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
Authors: H. Qiu, C. Yang, Z. Zhou, Y. Zhou, X. Wan, N. Li, K. Tao, Y. Li, X. Wu, Z. Chen, L. Men, Y. Xiong, E. Liang, C. Wang, D. Yang, Y. Zhai, R-H. Xu
Journal: Annals of Oncology (2024)
1711P Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Authors: J. McGrane, R. Frazer, A. Bahl, A. Challapalli, P. Roy, M. Tuthill, C. Forde, J.M. Malik, X-Y. Jiang, S.M. Alam, E.C.E. Jones, N. Charnley, W.M. Mohamed, N.O. Moon, D. Parslow, T.R. Geldart, C.L. Dyke, J.C. Tapia, D. Lee, G.J. Melendez-Torres
Journal: Annals of Oncology (2024)
1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Authors: L. Albiges, T.B. Powles, A. Sharma, B. Venugopal, J. Bedke, A. Borkowetz, G. Gravis, B.C. Özdemir, M.J. Schnabel, P. Dutailly, B. Qvick, V. Perrot, V. Gruenwald
Journal: Annals of Oncology (2024)
1730P Preliminary results of phase II study on preoperative intensity-modulated radiotherapy with concurrent PARP inhibitor for patients with non-metastatic inoperable or borderline operable extremity and trunk soft tissue sarcoma
Authors: N. Lu, L. Xu, Z. Zhao, Y-X. Zhang, Z-Y. Yang, L-H. Gong, X-X. Zhang, W. Liu, L. Wang, M. Li, Q. Chang, S-L. Wang, Q. Zhang, S-J. Yu
Journal: Annals of Oncology (2024)
1719O Multisarc: A randomized precision medicine study in advanced soft-tissue sarcomas
Authors: B. Verret, C. Bellera, P. Boudou Rouquette, E. Bompas, S. Watson, N. Penel, J.E. Kurtz, I. Desmoulins, F. Bertucci, E.B. Saada, M. Brahmi, N. Isambert, J-C. Thery, P. Dubray-Longeras, J-Y. Blay, Y. Laizet, J-F. Deleuze, I. Soubeyran, S. Mathoulin, A. Italiano
Journal: Annals of Oncology (2024)
1689TiP The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Authors: D. Galetta, A. Catino, D. Bafunno, G. Dalonzo, A. De Leo, V. Longo, E.S. Montagna, M. Montrone, I. Marech, F. Pesola, P. Pizzutilo
Journal: Annals of Oncology (2024)
1702P Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Authors: B.A. McGregor, M. Paul, W. Xie, W. Xu, M.A. Bilen, D.A. Braun, S. Berg, T. Zhang, R.R. McKay, D.F. McDermott, H. Hammers, T.K. Choueiri
Journal: Annals of Oncology (2024)
1718O EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)
Authors: N. Penel, A. Italiano, J. Wallet, L. Chaigneau, B. Verret, N. Firmin, S. Watson, T. Valentin, E. Bompas, F. Bertucci, M. Brahmi, A. Le Cesne, A. Brunot, M. Spalato Ceruso, M. Vanseymortier, E. Decoupigny, S. Taieb, M-C. Le Deley, C. Perrin, J-Y. Blay
Journal: Annals of Oncology (2024)
1700P Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Authors: Y-A. Vano, I. Hernandez, M. Bennamoun, V. Verkarre, C.M. Chevreau, M. Gross Goupil, C. Tournigand, D. Borchiellini, B. Laguerre, D. Maillet, P. Barthelemy, G. Gravis, E. Coquan, D. Pannier, N. Houede, S. Kotti, W-H. Fridman, C. Sautes-Fridman, C-M. Sun, S. Oudard
Journal: Annals of Oncology (2024)
1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT)
Authors: H. Abdel-Aty, C.L. Amos, L.C. Brown, Y. Yogeswaran, P. Niem, P. Dutey-Magni, V. Kasivisvanathan, R. Bennett, N. Clarke, A. Sachdeva, W. Cross, L. Farrelly, D. Matheson, C. Peedell, P. DIEZ, O. Naismith, M.K. Parmar, G. Attard, N. van As, N.D. James
Journal: Annals of Oncology (2024)
1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Authors: R. Nawfal, K. Semaan, M. Eid, M. Paul, R.M. Saliby, R. El Hajj Chehade, M. Machaalani, E. Saad, N. Phillips, J. Canniff, D. Vasseur, T. El Zarif, E. Yekeduz, M. Sun, S. Baca, D.A. Braun, W. Xie, K. Krajewski, T.K. Choueiri
Journal: Annals of Oncology (2024)
1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Authors: M. Catalano, G. Roviello, S. Buti, F. Massari, H. Li, S.H. Park, E. Grande, J. Kucharz, O. Fiala, A. Poprach, T. Buchler, E. Seront, J. Ansari, Z.W. Myint, D.M. Bhuva, A. Bamias, M. Ghosn, S. Andrey, M. Santoni, D. Santini
Journal: Annals of Oncology (2024)
1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER
Authors: D.A. Braun, Y. Wang, A. Yu, C. Pickering, D. Serie, T.K. Choueiri, W. Xu, M. Sun, S.V. Vemula, S. Gupta
Journal: Annals of Oncology (2024)
1712P Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Authors: J.H. Kim, S.J. Shin, W.K. Bae, S.H. Kim, J.Y. Kim, H-S. Im, I-H. Kim, I-H. Kim, K. Park, E. Kim, M. Choi, J.H. Lim, H. Kim, H-J. Kim, J. Jo, H.J. Lee, D. Kim, B.S. Sohn, I. Park, J.H. Park
Journal: Annals of Oncology (2024)
1726MO Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study
Authors: B.A. Wilky, J.C. Trent, A.M. Tsimberidou, M. Gordon, A.B. El-Khoueiry, A. Bullock, B.S. Henick, M. Agulnik, D. Mahadevan, A. Singh, W. Wu, M. Avagyan, J.M. Patel, J. Grossman, S.J. O'Day, G. Schwartz, R.L. Jones
Journal: Annals of Oncology (2024)
1707P A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Authors: E. Saad, R.M. Saliby, C. Steiner, K. Semaan, M. Eid, J.T. Horst, J. Lee, N. Phillips, R. Trowbridge, C. Lahav, M. Harel, G. Loewenthal, S. Raveh Shoval, I. Sela, A. Dicker, Y. Elon, T.K. Choueiri, W. Xu
Journal: Annals of Oncology (2024)
1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Authors: D. Kilari, A. Szabo, M.A. Bilen, Y. Ged, B.L. Maughan, C. Hwang, H. McManus, P.M. Coelho Barata, A. Desai, Y. Zakharia, H. Emamekhoo, A. Tripathi, T. Rose, P. Ghatalia, M.A. Reimers, E. Heath, J.M. King, B.I. Rini, J. Brugarolas, R.R. McKay
Journal: Annals of Oncology (2024)
1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Authors: R.M. Saliby, W. Xie, J.C. Wells, E. Saad, M. Eid, K. Semaan, C. Labaki, E. Ferrier, M. Zarba, H. Ebrahimi, C. Suarez Rodriguez, J.M. Ruiz, T.B. Powles, L.A. Wood, G.A. De Velasco Oria, K. Takemura, D.A. Braun, D.Y.C. Heng, T.K. Choueiri
Journal: Annals of Oncology (2024)
1714P Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Authors: S. Garinet, K. Semaan, J. Canniff, N. Phillips, M. Davidsohn, J.E. Berchuck, J. Li, A. Sadagopan, B. Fortunato, J. O’Toole, G-S.M. Lee, J.T. Horst, D. Freeman, J-H. Seo, M. Freedman, T.K. Choueiri, S. Baca, S. Viswanathan
Journal: Annals of Oncology (2024)
1699P Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Authors: R. Barragan-Carrillo, Z.B. Zengin, N. Dizman, H. Ebrahimi, L.A. Meza, S. Jaime-Casas, X. Li, T.B. Dorff, J. Hsu, N. Salgia, A. Chehrazi-Raffle, A. Tripathi, D. Castro, B. Mercier, G. Caporaso, K. Lee, S.K. Pal
Journal: Annals of Oncology (2024)
1688P Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Authors: Z.A. Ogunjimi, B.A. Akodu, A.C. Sowunmi, A.O. Ajose, R.O. Jimoh, C.E. Ifeanyi-Ezeaka, N. Bello, C.D. Obianyor
Journal: Annals of Oncology (2024)
1697P Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Authors: S. Sadeghi, R. Parikh, L.J. Appleman, D. Tsao-Wei, S. Groshen, M. Li, S.T. Tagawa, D.M. Nanus, A.M. Molina, M.C. Ornstein, B.I. Rini, R. Dreicer, D.I. Quinn, P.N. Lara
Journal: Annals of Oncology (2024)
1653P Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Authors: R.R. McKay, S. Nazari, A. Elliott, N. Smith, D. Kilari, None R. Garje, N. Agarwal, H. Beltran, E.S. Antonarakis, A. Bagrodia
Journal: Annals of Oncology (2024)
1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T
Authors: L. Albiges, M.T. Bourlon de los Rios, M. Chacon, H.J. Cutuli, Y.A. Lopez Chuken, J. Mota, I. Magri, M. Burotto, M.D.A. Luz, J. Menezes, E.P. Yanez Ruiz, M. Maruzzo, S. Bracarda, M. Breckenridge, D. Rathod, Z. Yu, H. Vezina, S. George
Journal: Annals of Oncology (2024)
1698P Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Authors: B. Venugopal, T.K. Choueiri, K.D. Penkov, L. Albiges, H. Uemura, J. Larkin, Y. Tomita, J. Wang, J. Hoffman, A. Gerhold-Ay, P. Kieslich, R.J. Motzer
Journal: Annals of Oncology (2024)
1647P Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Authors: G. Attard, U. Singh, Y. Xu, L. Farrington, K. Bell, K. Urtishak, W. Kim, J. Zhang, S. Parsons, K.Y. Li, M. Schwenk, W. Li, S. Wang
Journal: Annals of Oncology (2024)
1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Authors: A.J. Armstrong, L.J. Appleman, D.C. Danila, C-C. Lin, J.L. Lee, N. Matsubara, P.J. Ward, D.W. Pook, M. Kim, T.B. Dorff, S.C. Fischer, Y-C. Lin, L.G. Horvath, C. Sumey, Z. Yang, B.E. Decato, J.M. Englert, K.M. Smith, M. Lolkema, W.K. Kelly
Journal: Annals of Oncology (2024)
1626P Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations
Authors: A.A. Azad, N. Agarwal, N.D. Shore, J.C. Galceran, A.P. Fay, N. Matsubara, F. Saad, U. De Giorgi, J.Y. Joung, P.C. Fong, S. Zschäbitz, J.M. Piulats Rodriguez, S.M. Yip, G. Liu, L. DeAnnuntis, X. Lin, D. Laird, M. Kalac, K. Fizazi
Journal: Annals of Oncology (2024)
1713P A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Authors: J. Hou, J. Wen, R. Bhattacharya, Z. Wang, S.M. Sweet, A. Elfiky, L.S. Wang, R. Srivastava, J. Lu, V. Turzhitsky, R.R. McKay, G. Jayram, M. Sundaram, T. Cai, T. Cai
Journal: Annals of Oncology (2024)
1603P Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: W. Abida, L.J. Appleman, M-E. Taplin, Á. Juárez, L. Zhang, Y. Chen, N. Gupta, D. Saltzstein
Journal: Annals of Oncology (2024)
1628P Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Authors: V. Habouzit, M. Claudin, F. Borrelly, C. Richard, C. Bailly, P. Schwartz, E. Mairal, S. Chene, K. Hebert
Journal: Annals of Oncology (2024)
1629P Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Authors: K. Rahbar, M. Sarfaty, A. Peer, R. Leibowitz, M. Eiber, C. la Fougère, V. Prasad, W.P. Fendler, P. Rassek, E. Hasa, H. Dittmann, R.A. Bundschuh, K.M. Pabst, M. Kurtinecz, M. Korn, M. Essler, O. Sartor
Journal: Annals of Oncology (2024)
1654P TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Authors: J.S. de Bono, C. Helissey, K. Fizazi, J.P. Maroto Rey, G. Roubaud, E.S. Antonarakis, S.K. Sandhu, N.D. Shore, R. Ratta, B. Perez Valderrama, C. Vulsteke, L. Schafer, G. Marr, E. Zhao, A.F. Ward, J.M. Piulats Rodriguez
Journal: Annals of Oncology (2024)
1604P PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Authors: E.Y. Yu, V. Narayan, G. Esposito, R. Szmulewitz, Y. Lu, M. Lilly, J. Calais, G. Bratslavsky, M. Vasanawala, G.A. Ulaner, F. Pouliot, D. Laidley, N. Fleshner, F. Saad, Y. Menda
Journal: Annals of Oncology (2024)
1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: R. Berger, A.W. Tolcher, T.B. Dorff, S. Okubo, L.S. Abraham, R. Reilly, C. Stevenson, S. Wang, J. Arnold, S.R. Mudd, S. Alaei, J. Hong, D.I. Quinn, F. Saad, J. Powderly
Journal: Annals of Oncology (2024)
1619P Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Authors: A. Kristiansen, B. Sautois, A. Crippa, A. Mortezavi, A. Discacciati, C.T. Karlsson, A. Ullén, E. Jänes, G. Enblad, J. Oldenburg, J. Sandzén, M.N. Vigmostad, M.E. Hjälm-Eriksson, B. De Laere, M.H. Strijbos, C. Ghysel, J. Lindberg, M. Eklund, P. Ost, H. Grönberg
Journal: Annals of Oncology (2024)
1614P PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Authors: R.A. Madan, E. Mena Gonzalez, E.B.A. Chandran, J.B. Aragon-Ching, P.M. Arlen, L. Lindenberg, C. Chen, L. Cordes, S. McMahon, E. Lamping, A. Hankin, N. Williams, Y. McKinney, W. Figg, J.L. Gulley, P.L. Choyke, F. Karzai
Journal: Annals of Oncology (2024)
1621P Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Authors: A. Bjartell, A. Krzyzanowska, V. Liu, M. Tierney, E. Chen, M. Sjöström, M. Palominos, T. Royce, A. Kraft, A.C. Esteva, F. Feng
Journal: Annals of Oncology (2024)
1613P Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Authors: C. Mercinelli, N. Agarwal, S. Gupta, P. Grivas, P. Spiess, R. Li, G. Bratslavsky, J.M. Jacob, A. Basnet, D.C. Pavlick, R.P. Graf, J.S. Ross, A. Necchi
Journal: Annals of Oncology (2024)
1651P Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Authors: D. Tonnelet, J. Farce, L. Agrigoroaie, C. Merlin, A-S. Cottereau, S. Chene, C. Bailly, M. Bros, L. Mourey, M. Lacombe
Journal: Annals of Oncology (2024)
1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Authors: C. Kyriakopoulos, G. Chatta, A.L. Laccetti, N. Iannotti, A.O. Sokolova, S.J. Hotte, R. Tutrone, M.C. Markowski, L.T. Nordquist, R. Pili, F. Saad, J. Zhang, K. Villaluna, B. Younginger, R. Le Moigne, A. Cesano
Journal: Annals of Oncology (2024)
1624P Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Authors: M. Buffoni, A. Dalla Volta, F. Valcamonico, D.D. Apollo, A. Zivi, G. Procopio, P. Sepe, G. Del Conte, N. Di Meo, S. Foti, S. Zamboni, C. Messina, E. Lucchini, A. Rizzi, M. Ravanelli, M. Zamparini, F. Zacchi, N. Suardi, D. Farina, A. Berruti
Journal: Annals of Oncology (2024)
1609P PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Authors: W.P. Fendler, M. Karpinski, J. Hüsing, K. Claassen, H. Kajüter, F. Oesterling, V. Gruenwald, L. Umutlu, T. Telli, A. Merkel-Jens, A. Huesing, C. Kesch, S. Hoberück, P. Meyer, F. Kind, K. Rahbar, M. Schäfers, A. Stang, K. Herrmann, B.A. Hadaschik
Journal: Annals of Oncology (2024)
1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study
Authors: E. Jonasch, B.A. McGregor, P. Msaouel, T. Logan, E.T. Hall, M.A. Bilen, G.S. Falchook, B. Shuch, Y. Zakharia, R. Hauke, M. Gordon, A-R. Naqash, C.W. Ryan, R. Srinivasan, J. Xiao, W. Sun, M. Esguerra, G. Lu, J. Lager, T.K. Choueiri
Journal: Annals of Oncology (2024)